ArticlePLoS pathogens2023
A major locus confers triclabendazole resistance in Fasciola hepatica and shows dominant inheritance.
Article in PLoS pathogens, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 42 citations in OpenAlex.
- Exploring the functional and immunological diversity of the fatty acid-binding protein (FABP) family in Fasciola hepatica.Scientific reports · 2026Article
- Identification of stable miRNA references for qRT-PCR normalization in ovine fasciolosis.BMC genomics · 2026Article
- In vitro Host-Parasite Models Combined With Proteomics Reveal Cell Type-Specific Responses of Early Migrating Fasciola hepatica Juveniles.Molecular & cellular proteomics : MCP · 2026Article
- A practical miracidial motility assay for assessing Fasciola hepatica sensitivity to compounds in vitro.International journal for parasitology. Drugs and drug resistance · 2026Article
- Triclabendazole and Other Fasciolicides: Resistance ofAnimals : an open access journal from MDPI · 2026Review
- Serotonin signaling modulates growth and motility in juvenile Fasciola hepatica.PLoS neglected tropical diseases · 2026Article
- Whole genome sequencing in animal health: applications, challenges, and future directions.BMC veterinary research · 2026Review
- Curation of the Fasciola hepatica kinome as a resource for drug target discovery.BMC genomics · 2026Article
- Fasciolosis, a foodborne zoonotic trematode infection in cattle in Bangladesh: multifaceted validation of parthenogenecity and anthelmintic efficacy.Parasite (Paris, France) · 2026Article
- Genetic diversity and host-symbiont cophylogenetic analysis ofCurrent research in parasitology & vector-borne diseases · 2026Article
- Mitochondrial genome analysis supports zoonotic transmission of triclabendazole-resistant human fascioliasis in Peru.One health (Amsterdam, Netherlands) · 2025Article
- Structural Insights and Calcium-Switching Mechanism ofInternational journal of molecular sciences · 2025Article
- Design of a Multi-Epitope Vaccine Based onInternational journal of molecular sciences · 2025Article
- Albendazole specifically disrupts microtubules and protein turnover in the tegument of the cestode Mesocestoides corti.PLoS pathogens · 2025Article
- Independent origins and non-parallel selection signatures of triclabendazole resistance in Fasciola hepatica.Nature communications · 2025Article
- Chromosomal genome assembly resolves drug resistance loci in the parasitic nematode Teladorsagia circumcincta.PLoS pathogens · 2025Article
- Evaluating the In Vitro Anthelmintic Activity of Zinc Oxide Nanoparticles (ZnO-NPs) Against the Adult Stages of Fasciola hepatica.Veterinary medicine and science · 2025Article
- Development of multi-epitope Cathepsin L driven short peptide vaccine againstFrontiers in veterinary science · 2025Article
- Comparative analysis of anthelmintic treatments: impact on liver biomarkers and clinical recovery in sheep with fasciolosis.Frontiers in veterinary science · 2025Article
- Unraveling the microRNAs Involved in Fasciolosis: Master Regulators of the Host-Parasite Crosstalk.International journal of molecular sciences · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
Abstract
Fasciola hepatica infection is responsible for substantial economic losses in livestock worldwide and poses a threat to human health in endemic areas. The mainstay of control in livestock and the only drug licenced for use in humans is triclabendazole (TCBZ). TCBZ resistance has been reported on every continent and threatens effective control of fasciolosis in many parts of the world. To date, understanding the genetic mechanisms underlying TCBZ resistance has been limited to studies of candidate genes, based on assumptions of their role in drug action. Taking an alternative approach, we combined a genetic cross with whole-genome sequencing to localise a ~3.2Mbp locus within the 1.2Gbp F. hepatica genome that confers TCBZ resistance. We validated this locus independently using bulk segregant analysis of F. hepatica populations and showed that it is the target of drug selection in the field. We genotyped individual parasites and tracked segregation and reassortment of SNPs to show that TCBZ resistance exhibits Mendelian inheritance and is conferred by a dominant allele. We defined gene content within this locus to pinpoint genes involved in membrane transport, (e.g. ATP-binding cassette family B, ABCB1), transmembrane signalling and signal transduction (e.g. GTP-Ras-adenylyl cyclase and EGF-like protein), DNA/RNA binding and transcriptional regulation (e.g. SANT/Myb-like DNA-binding domain protein) and drug storage and sequestration (e.g. fatty acid binding protein, FABP) as prime candidates for conferring TCBZ resistance. This study constitutes the first experimental cross and genome-wide approach for any heritable trait in F. hepatica and is key to understanding the evolution of drug resistance in Fasciola spp. to inform deployment of efficacious anthelmintic treatments in the field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.